Browsing by Author "Çagirgan, S"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT)
    Ergene, U; Çagirgan, S; Pehlivan, M; Yilmaz, M; Tombuloglu, M
    Autologous peripheral blood stem cells transplantation (PBSCT) is a therapeutic option which can be used in various hematological neoplastic disorders; and it can prolong disease free survival and total survival and at times it may be curative. In this study, we investigated variables influencing PBSCT in 91 patients who had undergone PBSCT between 1998 and 2002 in our center, retrospectively. PBSC collection was performed after mobilization with G-CSF or chemotherapy plus growth factor. Only high dose chemotherapy was used for conditioning regimes. The median number of CD34+ was 11.5 x 10(6)/kg. Posttransplant neutrophil engraftment (> 500/mu L) was requiring a median of 10 days, it was 13 days for platelet engraftment (> 20,000/mu L). For neutrophil and platelet engraftment, we investigated; sex, age, diagnosis and CD34+ cells, the time interval between diagnosis and transplantation, number of apheresis, conditioning regime, growth factor initiation day as independent variables. In univariate analysis CD34+ cell number (> 10 x 10(6)/kg), time interval more than one year between diagnosis and transplantation and BEAM conditioning was found to be significant for neutrophil engraftment. But in multivariate analysis none of them was found to be significant. For platelet engraftment in univariate analysis CD34+ cell number (> 7 x 10(6)/kg), primary diagnosis of multiple myeloma initiation day of growth factor (> 2 day) was found to be significant. In multivariate analyses only CD34+ cell count was found to be significant (p = 0.005). In conclusion, as in previous studies we found that the only predictor of engraftment kinetics was CD34+ cell count. (c) 2006 Published by Elsevier Ltd.
  • No Thumbnail Available
    Item
    Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
    Tekgündüz, E; Demirkan, F; Vural, F; Göker, H; Özdogu, H; Kiki, I; Aydogdu, I; Kaynar, L; Erkurt, MA; Çagirgan, S; Besisik, S; Dagdas, S; Koca, E; Kadiköylu, G; Gündüz, E; Yilmaz, M; Beköz, H; Ural, AU; Bastürk, A; Arat, M; Albayrak, M; Öztürk, E; Akyol, A; Bolaman, AZ; Nevruz, O; Özkan, HA; Özgür, G; Altuntas, F
    Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.